Xcout Intel
Verona Pharma competitors & alternatives
The 12 closest competitors and alternatives to Verona Pharma among pharmaceuticals companies — ranked by similarity to what Verona Pharma actually does, not by market-cap band.
Subscribe to see Verona Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Verona Pharma
Verona Pharma plc focuses on innovative respiratory treatments and is headquartered in London, UK, alongside offices in the United States.
Verona Pharma at a glance
Verona Pharma is a pharmaceuticals company headquartered in United Kingdom, founded in 2005. It has raised at least $1B across the 4 funding rounds on record. Its most recent funding round, Private Placement, raised $650M in May 2024.
Verona Pharma funding rounds
At least $1B raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Private Placement | $650M | 14 named | |
| SEC Form D filing | $200.2M | — | |
| — | $200.2M | — | |
| SEC Form D filing | $44.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Verona Pharma news
Top 12 Verona Pharma competitors
Ranked by semantic similarity — how close each company is to Verona Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Chiesi Farmaceutici is a global biopharmaceutical group that researches, develops, and commercializes therapeutic solutions for patients. The company focuses primarily on respiratory health, rare diseases, and specialty care.
Similar pharmaceuticals company
Hudson Pharma is a branded generic pharmaceutical company that develops and manufactures treatments across segments such as respiratory, injectables, ophthalmic, and dermatology. The company serves doctors and patients globally by providing affordable, first-line therapies for conditions ranging from asthma and glaucoma to infections and vitamin deficiencies.
Similar pharmaceuticals company
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Similar pharmaceuticals company
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Pharmaceuticals, Biotechnology & Life Sciences
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Similar pharmaceuticals company
Almirall is a Spanish pharmaceutical company headquartered in Barcelona, focused primarily on researching, developing, and commercializing prescription medicines for dermatological diseases, with additional activities in areas such as respiratory health. It serves patients and healthcare professionals through products marketed in Spain and international markets.
Pharmaceuticals/Biotech
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Similar pharmaceuticals company
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Similar pharmaceuticals company
Theramex is a British pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis.
Similar pharmaceuticals company
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Similar pharmaceuticals company
GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally. Its research and development efforts focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
Similar pharmaceuticals company
Breath of Life Pharma, Ltd. operates within the pharmaceutical industry and provides a contact form and email newsletter signup on its website for updates and promotions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Verona Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Verona Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →